Letters
Incretins and pancreatic cancer
The BMJ and Dispatches gave only one side of the story
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4379 (Published 10 July 2013) Cite this as: BMJ 2013;347:f4379
- Richard I G Holt, professor in diabetes and endocrinology1
- 1University of Southampton, Southampton General Hospital, Southampton SO16 6YD, UK
The BMJ and Channel 4 Dispatches programme “Diet, Drugs and Diabetes” focused on possible dangers of incretin based treatments and alleged that the drug industry is hiding important safety data.1 Although drug safety and transparency are paramount, it is important to remember that no diabetes drug is completely safe. Clinicians and people with diabetes need to make a balanced decision about the risks and benefits of treatment, and this requires …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.